Back to search

Article

Myricetin suppressed DSS-induced colitis and promoted the therapeutic success of Infliximab in TNBS-induced colitis

2024-06-06

Abstract excerpt

<title>Abstract</title> <p>Infliximab (IFX) is widely used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). Still, long-term use may be ineffective or suggest some side effects. This study investigated the role of Myricetin, a flavonoid, alone and its complementary therapeutic potential in combination with IFX against UC, CH, and cancerization. DSS tr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
54bdbeff-a88b-59d6-a833-75d77b563df2
DOI
10.21203/rs.3.rs-4447222/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Myricetin suppressed DSS-induced colitis and promoted the therapeutic success of Infliximab in TNBS-induced colitisDOI 10.21203/rs.3.rs-4447222/v1
Select a neighboring publication to make it the new centre.